Customer success storiesgoldfinch bio
Goldfinch Bio the kidney company logo

Goldfinch Bio

Goldfinch Bio is a cutting edge, fast-growing biotechnology company that is singularly focused on discovering and developing precision therapies for kidney disease.

Just as the goldfinch was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for patients with kidney disease.

Key points

  • Goldfinch’s system at the time was not doing the job to a satisfactory level
  • E-WorkBook added the capabilities that Goldfinch was looking for, such as a scalable assay database
  • Goldfinch Bio can now access updates and new features as soon as they are released
  • It has seen improved data sharing with its external partners and collaborators

The challenge

As part of a focus on developing precision therapies for patients with kidney diseases, Goldfinch Bio had introduced an on-premise electronic lab notebook (ELN) which was used primarily as a document repository.

The system didn’t work as intended and the company was disappointed in the system’s performance. Goldfinch Bio also experienced issues concerning the level of service and support provided, with the cascading number of problems highlighting the need to quickly move to a more reliable informatics solution and provider. Goldfinch Bio also considered what capabilities, which their on-premise ELN was not providing, should be added with a new solution.

The solution

Goldfinch Bio re-evaluated their requirements and introduced The IDBS E-WorkBook platform, which runs on the Amazon Web Services (AWS) Cloud.

“One of the drivers for us, in addition to looking for a higher level of service, was adding capabilities that we knew we would need as a dynamic, growing company that we didn’t have previously. In particular, a big need we wanted to fill was a scalable assay database,” said Adam Tebbe, Senior Director of Informatics & IT, Goldfinch Bio.

“E-WorkBook not only offered just the standard ELN features, but also had the ability to actually load and aggregate the data together across studies and average assay endpoints for replicate measurements.”

The results

Goldfinch now has the ability to load and save different templates for different assays and then report and interrogate the data between the various runs it does.

“IDBS was able to create the environment quickly, and the fact we are able to easily connect to our AWS environment so that our production VPC can talk to The E-WorkBook Cloud is really nice,” said Tebbe.

“Everyone on the ‘Discovery’ side of the company gets an E-WorkBook Cloud account when they get hired. The system is used by chemists, biochemistry and biology. We also have pharmacology and computational research scientists adding data as well.

Goldfinch can now access new features and updates far sooner than a traditional on-premise system allows – improving service and end-user satisfaction. The E-WorkBook Cloud also schedules automatic backups without user intervention, ensuring the integrity and security of critical data.

In consideration of a SaaS deployment, Goldfinch Bio wanted to ensure a cost-effective solution in deploying a new technology.

“We did the analysis and found the total cost of ownership for the SaaS offering to be lower compared to deploying in our own environment,” explained Tebbe.

“IDBS is hosting the solution and is responsible for security and system management, but still allows for integrations in the cloud and ability to talk to it from any applications we deploy in our environment.”

The cloud is also enabling Goldfinch Bio to improve data sharing with its external partners and collaborators.

“Because of the nature of our company, we outsource work to CROs and other service providers. We also have valuable collaborations with key corporate partners and academic institutions,” said Tebbe.

“We use E-WorkBook to help us better integrate with these important external parties and improve overall collaboration workflows. We ask everyone we work with to contribute their data into the E-WorkBook to help us consolidate the data from different sources.”

How IDBS platforms use AWS

The IDBS E-WorkBook platform leverages cloud-native technologies and design approaches to ensure that IDBS can provide a highly available and secure system for its customers. The technologies used are chosen with key requirements in mind.

AWS provides the largest breadth of services of any cloud provider and the technologies adopted at IDBS range from data storage and container orchestration to a content delivery network. IDBS is, for example, leveraging AWS Aurora, which is a database technology designed for the cloud, providing performance, resilience and scalability. For operational needs, IDBS leverages serverless technologies such as Lambda to ensure systems can be deployed and monitored in an automated fashion.

In addition to using AWS technologies, IDBS also engages with AWS to undergo ‘Well Architected’ reviews, which provide a means to help ensure IDBS is building systems in a secure, scalable and resilient way.

About Goldfinch Bio

Goldfinch is singularly focused on discovering and developing precision therapies for patients with kidney disease.

Chronic kidney disease (CKD) is a growing, global health epidemic that places an enormous social and economic burden on patients, their families, and society. CKD is a driver of mortality across age, race, and stage of disease progression, affecting over 1 in 9 people worldwide. The impact of CKD is amplified by the fact that It is not one disease, but encompasses several diseases, each with distinct causes.

Advances in kidney transplantation and dialysis over half a century ago extended life for patients with kidney failure, yet the current standard of care for patients with kidney disease remains inadequate, and there is an urgent need for new treatment options.

Recent breakthroughs in genetics and biology have generated an unparalleled understanding of the biological pathways that drive kidney disease. Goldfinch Bio is uniquely positioned to translate these discoveries into new therapies that target the molecular causes for diseases of the kidney.

Want to speak to an expert?

Contact us

Customer success